Josep Gámez

Hospital Clínic de Barcelona — Spain

Medicine · Health Sciences

37h-index6.2kcitations163works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyotrophic Lateral Sclerosis Research(33), Neurogenetic and Muscular Disorders Research(32), Genetic Neurodegenerative Diseases(29), Myasthenia Gravis and Thymoma(24), Peripheral Neuropathies and Disorders(20)

Publications157 total

Cost Analysis of Immunoglobulin Maintenance Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy in Spain
PharmacoEconomics - Open·2026Open Access
The Results of <scp>ADVANCE</scp>‐<scp>CIDP IVIG</scp> Trial: Intravenous Immunoglobulin 10% Therapy With <scp>GAMMAGARD LIQUID</scp>/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
European Journal of Neurology·2025Open Access
Myasthenia gravis concurrent with Parkinson’s disease in a Spanish cohort. Causation or correlation?
Neurological Sciences·2024· 3 cited
Clinicopathological correlates in the frontotemporal lobar degeneration–motor neuron disease spectrum
Brain·2024· 10 citedOpen Access
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
Neurology·2023· 60 citedOpen Access
Evidence of high compliance and fatigue in mask adherence in two mandates in Barcelona, Spain: a naturalistic observational study
Public Health·2023· 3 citedOpen Access
Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial
The Lancet Neurology·2023· 38 citedOpen Access
A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease
British Journal of Clinical Pharmacology·2022· 7 cited
Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients
Neurology·2022· 2 citedOpen Access
Safety of <scp>mRNA COVID</scp>‐19 vaccines in patients with well‐controlled myasthenia gravis
Muscle & Nerve·2022· 10 citedOpen Access
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
Journal of Neurology·2022· 34 citedOpen Access
Dystrophinopathy Phenotypes and Modifying Factors in <scp><i>DMD</i></scp> Exon 45–55 Deletion
Annals of Neurology·2022· 14 citedOpen Access
HLA-DQB1*05:02, *05:03, and *03:01 alleles as risk factors for myasthenia gravis in a Spanish cohort
Neurological Sciences·2022· 14 cited
Serum IgG and Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates with Improvement in MG-ADL in Generalized Myasthenia Patients (S25.007)
Neurology·2022· 3 cited
Randomized phase 2 study of<scp>ACE</scp>‐083, a<scp>muscle‐promoting</scp>agent, in facioscapulohumeral muscular dystrophy
Muscle & Nerve·2022· 24 citedOpen Access
P.0426 Proof-of-concept study testing SOM3355 for the treatment of chorea symptoms in Huntington's disease
European Neuropsychopharmacology·2021· 1 cited
Efficacy and safety with &gt;3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis
Journal of the Neurological Sciences·2021
F40 Proof-of-concept study testing SOM3355, a VMAT2 inhibitor for the treatment of chorea in huntington’s disease
2021
Confirmation of early non-bulbar onset of amyotrophic lateral sclerosis in Spanish league soccer players.
Journal of the Neurological Sciences·2021· 9 cited
Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Neurology·2021· 18 cited
page 1 of 8Next →

Frequent Co-authors

Antoni L. Andreu(12), Carlos Cervera(11), María Salvadó(5), Montserrat Baiget(5), Michio Hirano(5), N. Raguer(4), Eduardo F. Tizzano(4), Julio Montoya(4), Maya R. Vilà(4), Bjarne Udd(3), Guillaume Bassez(3), Ralf Krahe(3), Germán Morís(3), Adolfo López de Munaín(3), Victoria Álvarez(3), Ricard Rojas‐García(3), Carles Cervera(3), Simó Schwartz(3), José M. Ponseti(3), Ramón Vilallonga(3)